P. C. Arora and C. A. Portell, Novel therapies for relapsed/refractory mantle cell lymphoma, Best Pract Res Clin Haematol, vol.31, issue.1, pp.105-113, 2018.

X. Gong, L. M. Litchfield, and Y. Webster, Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib, Cancer Cell, vol.32, issue.6, pp.761-776, 2017.

J. A. Dempsey, E. M. Chan, T. F. Burke, and R. P. Beckmann, Abstract LB-122: LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer, Cancer Res, vol.73, issue.8, 2013.

P. Martin, N. L. Bartlett, and K. A. Blum, A Phase I Trial of Ibrutinib Plus Palbociclib in Previously Treated Mantle Cell Lymphoma, Blood, vol.133, issue.11, pp.1201-1204, 2019.

B. D. Cheson, S. J. Horning, and B. Coiffier, Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group, J Clin Oncol, vol.17, issue.4, pp.1244-1253, 1999.

R. I. Fisher, S. H. Bernstein, and B. S. Kahl, Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma, J Clin Oncol, vol.24, issue.30, pp.4867-4874, 2006.

A. Goy, R. Sinha, and M. E. Williams, Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study, J Clin Oncol, vol.31, issue.29, pp.3688-3695, 2013.

S. Rule, W. Jurczak, and M. Jerkeman, Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study, Leukemia, vol.32, issue.8, pp.1799-1803, 2018.

M. Wang, S. Rule, and P. L. Zinzani, Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial, Lancet, vol.391, pp.659-667, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01726196

M. L. Wang, S. Rule, and P. Martin, Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N Engl J Med, vol.369, issue.6, pp.507-516, 2013.

X. Zhao, T. Lwin, and A. Silva, Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma, Nat Commun, vol.8, p.14920, 2017.

C. S. Tam, M. A. Anderson, and C. Pott, Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma, N Engl J Med, vol.378, issue.13, pp.1211-1223, 2018.

D. Chiron, D. Liberto, M. Martin, and P. , Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma, Cancer Discov, vol.4, issue.9, pp.1022-1035, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02490276

S. C. Tate, S. Cai, and R. T. Ajamie, Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor